Pleiotrophin inhibits HIV infection by binding the cell surface-expressed nucleolin.
The growth factor pleiotrophin (PTN) has been reported to bind heparan sulfate and nucleolin, two components of the cell surface implicated in the attachment of HIV-1 particles to cells. Here we show that PTN inhibits HIV-1 infection by its capacity to inhibit HIV-1 particle attachment to the surface of permissive cells. The beta-sheet domains of PTN appear to be implicated in this inhibitory effect on the HIV infection, in particular the domain containing amino acids 60-110. PTN binding to the cell surface is mediated by high and low affinity binding sites. Other inhibitors of HIV attachment known to bind specifically surface expressed nucleolin, such as the pseudopeptide HB-19 and the cytokine midkine prevent the binding of PTN to its low affinity-binding site. Confocal immunofluorescence laser microscopy revealed that the cross-linking of surface-bound PTN with a specific antibody results in the clustering of cell surface-expressed nucleolin and the colocalization of both PTN and nucleolin signals. Following its binding to surface-nucleolin, PTN is internalized by a temperature sensitive mechanism, a process which is inhibited by HB-19 and is independent of heparan and chondroitin sulfate proteoglycans. Nevertheless, proteoglycans might play a role in the concentration of PTN on the cell surface for a more efficient interaction with nucleolin. Our results demonstrate for the first time that PTN inhibits HIV infection and suggest that the cell surface-expressed nucleolin is a low affinity receptor for PTN binding to cells and it is also implicated in PTN entry into cells by an active process.
Said
Elias A
EA
UPR 2228 CNRS, UFR Biomédicale des Saints-Pères, Paris, France. elias.said@umontreal.ca
Courty
José
J
Svab
Josette
J
Delbé
Jean
J
Krust
Bernard
B
Hovanessian
Ara G
AG
D000595:Amino Acid Sequence; D002352:Carrier Proteins / Q000378:metabolism / Q000502:physiology*; D011508:Chondroitin Sulfate Proteoglycans / Q000494:pharmacology; D016207:Cytokines / Q000378:metabolism / Q000502:physiology*; D004705:Endocytosis; D006678:HIV / Q000187:drug effects / Q000472:pathogenicity; D015658:HIV Infections / Q000517:prevention & control*; D006367:HeLa Cells; D019812:Heparan Sulfate Proteoglycans / Q000494:pharmacology; D006801:Humans; D008565:Membrane Proteins / Q000378:metabolism; D010446:Peptide Fragments / Q000494:pharmacology*; D010750:Phosphoproteins / Q000378:metabolism*; D011485:Protein Binding; D016601:RNA-Binding Proteins / Q000378:metabolism*; D013696:Temperature; D000097796:Nucleolin
D002352:Carrier Proteins; D011508:Chondroitin Sulfate Proteoglycans; D016207:Cytokines; D019812:Heparan Sulfate Proteoglycans; D008565:Membrane Proteins; D010446:Peptide Fragments; D010750:Phosphoproteins; D016601:RNA-Binding Proteins; D000097796:Nucleolin; C066845:pleiotrophin